Oxynorm

Active Ingredient:: Oxycodone Hydrochloride
Origin:: EU

Oxynorm (Oxycodone Hydrochloride)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone hydrochloride, the active ingredient in Oxynorm, is an opioid analgesic presented as a oral formulation for systemic use. It is prescribed for the management of moderate to severe pain in adult patients when other analgesics are insufficient. GNH India supplies Oxynorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH India supplies Oxynorm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Mundipharma Bv

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxynorm is an opioid analgesic that acts on the central nervous system to relieve pain in several clinical contexts.

Acute postoperative pain: provides rapid relief following surgical procedures.
Cancer‑related pain: helps control persistent pain associated with malignant disease.
Severe chronic non‑cancer pain: used when other treatments have not achieved adequate control.

How It Works

Oxynorm delivers oxycodone hydrochloride, which binds primarily to µ‑opioid receptors in the central nervous system. This receptor activation inhibits the release of excitatory neurotransmitters, reduces neuronal excitability, and modifies pain signal transmission, resulting in an overall decrease in the perception of pain.

Side Effects

Adverse reactions may range from mild to life‑threatening and should be monitored during therapy.

Common Side Effects

Constipation: reduced gastrointestinal motility.
Nausea and vomiting: upset stomach and emesis.
Drowsiness: increased sedation and reduced alertness.
Dry mouth: decreased salivary flow.
Dizziness: light‑headed sensation, especially when standing.
Pruritus: mild itching of the skin.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing that can be fatal.
Severe hypotension: marked drop in blood pressure.
Opioid use disorder: risk of dependence, tolerance, and addiction.
Seizures: rare occurrence of convulsive episodes.
Anaphylaxis: acute allergic reaction with airway compromise.
adrenal insufficiency: rare hormonal imbalance affecting stress response.

Precautions & Warnings

When prescribing Oxynorm, clinicians should evaluate patient history and monitor for potential complications.

Assess renal and hepatic function: adjust use if impairment is present.
Evaluate respiratory status: avoid in patients with compromised breathing.
Review concomitant CNS depressants: increased sedation risk.
Counsel on constipation management: use laxatives or stool softeners as needed.
Monitor for signs of dependence or misuse: educate patients on safe use.
Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Oxynorm can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

Benzodiazepines: combined central nervous system depression can be fatal.
Barbiturates: additive respiratory depression risk.
Muscle relaxants: heightened sedative effects.
Alcohol: synergistic depressant effect on respiration and cognition.
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase oxy‑c‑tolerance.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may alter metabolism.
Anticholinergic agents: may worsen constipation.
Diuretics: potential for orthostatic hypotension.
Antihistamines: increased drowsiness.
NSAIDs: heightened risk of gastrointestinal bleeding.

Frequently Asked Questions

Oxynorm contains oxycodone hydrochloride, an opioid analgesic prescribed to treat moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic non‑cancer pain when other analgesics are insufficient.

Oxycodone hydrochloride binds to µ‑opioid receptors in the brain and spinal cord, inhibiting the release of pain‑transmitting neurotransmitters and reducing neuronal excitability, which lowers the perception of pain.

The appropriate dose of Oxynorm is determined by a qualified prescriber based on the patient’s pain severity, prior opioid exposure, age, weight, and overall health status.

Oxynorm is classified as a high‑risk medication in pregnancy and lactation; it may cause fetal harm or be excreted in breast milk, so it should only be used if the potential benefit justifies the risk and under strict medical supervision.

To order Oxynorm, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Oxynorm (oxycodone) offers a balanced potency profile and oral bioavailability compared with morphine or hydromorphone, providing effective pain relief with a predictable dosing schedule, though individual response and side‑effect risk may differ.

Oxynorm should be stored at temperatures below 25 °C, in its original container, protected from moisture, heat and direct sunlight to maintain potency and prevent degradation.

Oxynorm is administered orally, typically as a tablet or capsule, and should be taken exactly as prescribed, with or without food according to the label instructions.

The most serious risks include respiratory depression, severe hypotension, opioid dependence, and the potential for overdose, all of which require careful monitoring and immediate medical attention if symptoms arise.

Oxynorm is contraindicated in individuals with known hypersensitivity to oxycodone, those with significant respiratory depression, acute or severe asthma, and patients who are actively abusing opioids or other central nervous system depressants.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.